Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 5.6% – Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL) shares traded down 5.6% during trading on Thursday . The company traded as low as $2.20 and last traded at $2.20. 210,469 shares traded hands during trading, a decline of 80% from the average session volume of 1,070,862 shares. The stock had previously closed at $2.33.

Wall Street Analysts Forecast Growth

AUTL has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Stock Performance

The stock has a market cap of $590.72 million, a PE ratio of -1.83 and a beta of 2.05. The business’s fifty day moving average price is $2.70 and its 200-day moving average price is $3.56.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the company earned ($0.26) earnings per share. Analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its stake in shares of Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC lifted its holdings in Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Great Point Partners LLC boosted its stake in Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares during the period. Armistice Capital LLC raised its position in shares of Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after buying an additional 1,578,000 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its stake in Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after acquiring an additional 925,000 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.